Magen, commenced on November 2011 within Gefen, develops the SpineShield, TendonShield and NerveShield to address the $1B worldwide orthopedic anti-adhesion market. Adhesions usually form in the first 30 days after orthopedic surgery. Adhesion‐related complications are common, result in complications such as severe pain and /or impaired function. Magen products offer a physical barrier and mechanical strength to separate and provide a space between scar and normal tissues (e.g. the SpineShield protects the dura and spinal cord from formation of unwanted postoperative scars, fibrosis and blood penetration following laminectomy). Succeeding healing, the barrier is untwined out of the body. The SpineShield acquired CE Mark and successfully demonstrated its activity in 3 patients.